Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma (EOC)

Core Viewpoint - Agilent Technologies Inc. has received FDA approval for PD-L1 IHC 22C3 pharmDx as the only FDA-approved companion diagnostic for identifying first-line patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma whose tumors express PD-L1 and may be eligible for treatment with KEYTRUDA® [1] Group 1 - The FDA has approved PD-L1 IHC 22C3 pharmDx as a companion diagnostic [1] - This diagnostic is specifically indicated for patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma [1] - The approval aids in identifying patients whose tumors express PD-L1 and who may be eligible for KEYTRUDA® treatment [1]